Autolus Therapeutics (AUTL) Income from Continuing Operations (2017 - 2026)
Autolus Therapeutics' (AUTL) quarterly Income from Continuing Operations came in at 90360000.0 in Q4 2025, down 227.32% YoY from 70970699.9 in Q4 2024, and down 14.21% on a QoQ basis from 79118000.0 in Q3 2025.
Autolus Therapeutics (AUTL) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Autolus Therapeutics (AUTL) has 9 years of Income from Continuing Operations data on file, last reported at 90360000.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 227.32% year-over-year to 90360000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 287556000.0 (down 30.32% YoY) and the FY2025 annual result came in at 287556000.0, down 30.32% from the prior year.
- Income from Continuing Operations slipped to 90360000.0 in Q4 2025, from 79118000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 26979000.0 in Q4 2022 to a low of 90360000.0 in Q4 2025.
- A 5-year average of 50380300.0 and a median of 44159500.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations jumped 64.23% — and 2025, when it tumbled 227.32%.
- Tracing AUTL's Income from Continuing Operations over 5 years: stood at 41708000.0 in 2021, then soared by 35.31% to 26979000.0 in 2022, then tumbled by 186.04% to 77171000.0 in 2023, then jumped by 64.23% to 27606000.0 in 2024, then plunged by 227.32% to 90360000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 90360000.0 (Q4 2025), 79118000.0 (Q3 2025), and 47917000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Autolus Therapeutics | 763.37 Mn | 561.74 Mn | 25.22 Mn | -39.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.11 Mn |
| Dec 31, 2025 | -90.36 Mn |
| Sep 30, 2025 | -79.12 Mn |
| Jun 30, 2025 | -47.92 Mn |
| Mar 31, 2025 | -70.16 Mn |
| Dec 31, 2024 | -27.61 Mn |
| Sep 30, 2024 | -82.09 Mn |
| Jun 30, 2024 | -58.27 Mn |
| Mar 31, 2024 | -52.69 Mn |
| Dec 31, 2023 | -77.17 Mn |
| Sep 30, 2023 | -45.85 Mn |
| Jun 30, 2023 | -45.55 Mn |
| Mar 31, 2023 | -39.81 Mn |
| Dec 31, 2022 | -26.98 Mn |
| Sep 30, 2022 | -42.77 Mn |
| Jun 30, 2022 | -42.06 Mn |
| Mar 31, 2022 | -37.06 Mn |
| Dec 31, 2021 | -41.71 Mn |
| Sep 30, 2021 | -33.99 Mn |
| Jun 30, 2021 | -33.17 Mn |